A trial of trastuzumab deruxtecan for people with oesophageal, stomach or gastro oesophageal junction cancer (DECIPHER)

This trial is looking at trastuzumab deruxtecan after surgery. It’s for people with cancer of the:

• stomach

• food pipe (oesophagus)

• area where the stomach joins the food pipe (gastro oesophageal junction)

And both of the following:

• a large amount of the HER2 protein on the cancer cells - this is called HER2 positive cancer

• small amounts of cancer DNA in the bloodstream after surgery - this is called circulating tumour DNA or ctDNA

This trial is for people with cancer that has not spread to another part of the body. And it has been completely removed with surgery.